Reta and tesa before and after results vary by dose, diet, and timeline. Learn what real-world retatrutide and tesamorelin changes look like and what to track.
Reta and tesa before and after results usually show a steady drop in body weight, a visibly leaner midsection, and modest changes in muscle fullness over 8 to 24 weeks. Retatrutide (RETA) drives most of the scale movement, while tesamorelin (TESA) primarily targets visceral belly fat and supports natural growth hormone release. Neither peptide produces overnight change, and outcomes depend heavily on diet, training, sleep, dose, and consistency.
What Reta and Tesa Actually Are
Retatrutide is an investigational triple agonist that activates GLP-1, GIP, and glucagon receptors. It is not FDA-approved for any use and remains in phase 3 clinical trials for obesity and related conditions.
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It is FDA-approved as Egrifta for reducing visceral adipose tissue in adults with HIV and lipodystrophy, and it is widely used off-label for body composition.
The two peptides work through different pathways, which is why some people stack them. RETA reduces appetite and total fat mass, while TESA targets deep abdominal fat and may help support lean tissue.
Typical Reta and Tesa Before and After Timeline
Most before-and-after comparisons follow a similar arc. The table below summarizes what tends to change and roughly when it happens.
| Timeframe | RETA-related changes | TESA-related changes |
|---|---|---|
| Weeks 1–2 | Appetite suppression, reduced food noise, early water-weight loss, possible nausea | Minimal visible change; IGF-1 levels begin rising |
| Weeks 4–8 | Noticeable weight loss, looser clothing, improved blood sugar markers | Early reductions in waist circumference |
| Weeks 12–16 | Double-digit percentage weight loss in many users; face and waist look leaner | Measurable visceral fat reduction; some users report better gym recovery |
| Weeks 20–24+ | Progress slows or plateaus; dose changes are common | Continued but slower visceral fat change; plateaus without diet adjustments |
In clinical trials, retatrutide produced up to roughly 24% body weight reduction at 48 weeks in the highest-dose group. Tesamorelin trials showed about 15% to 18% reductions in visceral adipose tissue over 26 weeks.
What Shows Up in Before and After Photos
Most reta before and after pictures focus on the face, waist, and shoulders. Common visible changes include:
- A narrower waistline and less lower-belly protrusion
- A leaner face, jaw, and neck
- Looser fit through the chest, arms, and thighs
- More visible muscle definition once body fat drops
Photos from tesamorelin reddit before and after threads tend to look subtler, because visceral fat sits behind the abdominal wall. That kind of fat loss often shows up in waist measurements before it shows up in photos.
Lighting, posture, hydration, and even sodium intake can change a photo overnight. Take standardized pictures at the same time of day, in the same lighting and pose, roughly every four weeks.
How Reta and Tesa Compare to Other Options
Reta and tesa are not the only compounds people track with before-and-after documentation. The table below compares common options by mechanism and typical visible change.
| Option | Primary mechanism | Typical before-and-after change |
|---|---|---|
| Retatrutide | Triple GLP-1/GIP/glucagon agonist | Large total body weight loss |
| Tesamorelin | GHRH analog that raises endogenous GH | Visceral fat reduction, modest waist change |
| Semaglutide | GLP-1 agonist | Steady weight loss, strong appetite control |
| Tirzepatide | Dual GLP-1/GIP agonist | Faster scale change than semaglutide in trials |
| HGH | Exogenous growth hormone | Body composition shifts, water retention, higher cost |
| CJC-1295 / Ipamorelin | GHRH plus ghrelin receptor agonist | Gradual recovery and body composition change |
People who want faster scale movement often compare semaglutide before and after photos with tirzepatide before and after 3 months results, since both are FDA-approved and widely prescribed. Growth hormone changes tend to be slower and are often confounded by water retention.
Stacking Variants People Ask About
Some users pair retatrutide with mitochondrial peptides, and searches for reta and mots-c before and after reflect that interest. MOTS-c is studied for metabolic regulation, but human body composition data is limited, so it should not be treated as a proven fat-loss add-on.
Adding more compounds does not automatically improve results. More peptides usually means more variables, more side effects, and a harder time telling which product is actually doing the work.
Side Effects, Safety, and Monitoring
- RETA: nausea, vomiting, diarrhea, constipation, reduced appetite, injection site reactions, and gallbladder or pancreatic concerns reported across the GLP-1 drug class.
- TESA: injection site reactions, joint pain, swelling, elevated IGF-1, increased blood sugar, and a warning about tumor growth potential in people with active malignancy.
Both compounds call for medical supervision and regular bloodwork. Retatrutide is not approved for human use in the United States, so any supply is unregulated and purity is not guaranteed. Tesamorelin is approved only for HIV-associated lipodystrophy, which means every other use is off-label.
Anyone considering these peptides should talk with a licensed healthcare professional first, especially with a personal or family history of thyroid cancer, pancreatitis, or hormone-sensitive conditions.
Bottom Line
Reta and tesa before and after results are real but gradual, and they depend on far more than the peptides themselves. Expect appetite changes and weight loss from retatrutide, visceral fat reduction from tesamorelin, and the biggest visible differences after 12 weeks or more of consistent diet and training. Track progress with measurements and standardized photos rather than relying on the scale alone.
Frequently Asked Questions
How long does it take to see results from reta and tesa?
Most people notice appetite changes from retatrutide within the first one to two weeks, but visible body composition changes usually take 8 to 12 weeks. Tesamorelin works more slowly on visceral fat, with measurable waist changes often appearing around 12 to 16 weeks. Full results are typically judged at 24 weeks or later.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational drug still in phase 3 trials and is not FDA-approved for human use in the United States. Any product sold as retatrutide is unregulated, and its purity and dosing cannot be verified. Tesamorelin, by contrast, is FDA-approved as Egrifta for HIV-associated lipodystrophy.
Can you stack retatrutide and tesamorelin?
Some people stack them because they work through different pathways: appetite and total fat loss versus visceral fat and growth hormone support. There is no clinical trial data on the combination, so the safety profile and ideal dosing are unknown. A healthcare provider should supervise any stacking and monitor IGF-1, blood sugar, and liver and pancreatic markers.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.